急性髓系白血病中FLT3基因突变的研究进展  

Research progress of FLT3 gene mutation in acute myeloid leukemia

作　　者：江伟 高玉娟(综述)[1] 苏雁华(审校)[1] JIANG WEI;GAO Yujuan;SU Yanhua(Department of Hematology,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,哈尔滨150001

出　　处：《临床与病理杂志》2020年第3期718-722,共5页Journal of Clinical and Pathological Research

基　　金：黑龙江省卫生厅基金项目(2007-171)。

摘　　要：急性髓系白血病(acute myelogenous leukemia,AML)是一种常见的造血系统恶性肿瘤。AML患者中约有30%会发生FLT3基因突变,ITD突变是最常见的FLT3突变类型之一。携带FLT3-ITD突变的患者具有高白细胞的表现,并且预后不良。越来越多的证据表明FLT3突变状态在疾病整个过程中持续进展,因此早期对FLT3突变的诊断可更好地了解患者的病情,实现针对性治疗。同时,FLT3抑制剂对改善AML的治疗效果非常重要。Acute myeloid leukemia(AML)is a type of malignant tumor of the hematopoietic system.Approximately 30%of AML patients develop FLT3 mutations,one of the most common types of FLT3 mutations,and patients with FLT3-ITD mutations have high white blood cell counts with poor prognosis.There is increasing evidence that the FLT3 mutation status continues to progress throughout the disease,so early diagnosis of FLT3 mutations is better for understanding of patient’s condition and targeted treatment.At the same time,FLT3 inhibitors are very important to improve the therapeutic effect of ALL.

关 键 词：急性髓系白血病 预后 FLT3-ITD FLT3抑制剂 

分 类 号：R733.71[医药卫生—肿瘤]